Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
76.05 EUR | 0.00% | 0.00% | 0.00% |
26/04 | BRENNTAG : Barclays keeps a Sell rating | ZD |
23/04 | Baader lowers Brenntag to 'Add' and target to 85 euros | DP |
Strengths
- With regards to fundamentals, the enterprise value to sales ratio is at 0.75 for the current period. Therefore, the company is undervalued.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Diversified Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
0.00% | 11.81B | - | ||
-0.24% | 77.64B | B | ||
+2.08% | 32.83B | C | ||
+8.66% | 17.99B | B | ||
+9.94% | 11.61B | A- | ||
-0.10% | 10.35B | - | ||
+6.35% | 9.91B | A- | ||
-2.65% | 9.2B | C- | ||
+4.42% | 8.32B | B | ||
-0.59% | 6.54B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BNR Stock
- BNR Stock
- Ratings Brenntag